



(19) Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) Publication number:

0 573 777 A1

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 93107265.6

(51) Int. Cl.5: **A61K 31/35, A61K 35/78,
A61K 9/10**

(22) Date of filing: 05.05.93

(30) Priority: 11.05.92 IT MI921123

(43) Date of publication of application:
15.12.93 Bulletin 93/50

(84) Designated Contracting States:
**AT BE CH DE DK ES FR GB GR IE IT LI LU MC
NL PT SE**

(71) Applicant: IdB Holding S.p.A.
Via Ripamonti, 99
I-20141 Milano(IT)

(72) Inventor: Seghizzi, Roberto
Via Ripamonti, 99
I-20141 Milano(IT)
Inventor: Gabetta, Bruno
Via Ripamonti, 99
I-20141 Milano(IT)
Inventor: Morazzoni, Paolo
Via Ripamonti, 99
I-20141 Milano(IT)

(74) Representative: Minoja, Fabrizio
Studio Consulenza Brevettuale
Via Rossini, 8
I-20122 Milano (IT)

(54) Oral pharmaceutical compositions containing anthocyanosides.

(57) Oral pharmaceutical compositions containing high content anthocyanosides, preferably higher than 80% w/w, suspended in fractionated coconut oil have higher bioavailability than water solutions or suspensions in other lipophilic carriers.

EP 0 573 777 A1

The present invention concerns pharmaceutical compositions for oral use containing extracts with high content in anthocyanosides (HCA) as the active principle.

5 The fruits of many plants, such as Vaccinium myrtillus, Ribes nigrum, Vitis vinifera and Sambucus nigra, are starting materials for the preparation of anthocyanosides containing extracts, which are used in therapy in the conditions of impaired microcirculation and in ophthalmology for the treatment of myopias and visual fatigue.

10 The pharmacological activity of said extracts is mainly due to their content in anthocyanosides. In the V. myrtillus fruits, for instance, 3-O-galactosides and 3-O-arabinosides of cyanidin, delphinidin, petunidin, peonidin and malvidin aglycones are present in well defined ratios. The anthocyanoside content in the commercial V. myrtillus extracts ranges from 2 to 40%.

15 The present trend is generally to prepare standardized and normalized high content extracts, i.e. containing more than 50% and preferably more than 80% of anthocyanosides (w/w). With this aim, a process for the preparation of high content (>80%) anthocyanosides extracts (HCA), in the natural ratios, starting from fruits or from low content extracts, has been recently developed (EP 0412300 A2).

20 15 Tests of oral administration in the animal of HCA aqueous solutions have however shown a low absorption of these active principles having flavilium salts structure, which are poorly bioavailable notwithstanding their good water solubility. To improve their oral absorption, the administration of HCA suspended in lipophilic carriers, comprising vegetable oils, such as peanut oil, soybean oil (i.e. long chain fatty acids triglycerides mixtures), semisynthetic vegetable oils, such as fractionated coconut oil (i.e. medium chain fatty acids triglycerides mixtures), unsaturated polyglycolised glycerides (GPGI) and mineral oil, such as liquid paraffin, has been studied.

25 It has surprisingly been found that fractionated coconut oil is the only carrier, among the cited ones, able to remarkably improve the oral absorption of HCA when used as a suspending medium.

30 25 The present invention relates therefore to pharmaceutical compositions containing high content anthocyanosides (HCA), particularly having a content higher than 50% and preferably higher than 80% (w/w), suspended in fractionated coconut oil, said compositions substantially improving the oral absorption of the active principles.

35 The suspensions are prepared by suspending micronized HCA in the fractionated coconut oil, at room temperature, by means of a turbine stirrer. HCA are suspended in the lipophilic carrier in percentages ranging from 2% to 10% w/w, preferably from 4 to 8%. Conventional rheological modifiers can also be added to optimize the physical stability of the suspensions, as well as conventional surfactants, such as soybean lecithin, to ensure a good wettability of the HCA powder.

40 The resulting oily suspensions may then be directly distributed in gelatine capsules or absorbed on suitable excipients, such as colloidal silicon dioxide, starch or mannitol. In this second instance kneads are obtained which are granulated and distributed in sachets or used for preparing tablets.

45 The oral absorption of HCA suspended in different lipophilic carriers was compared with that of an aqueous solution thereof. With this aim, groups of male rats (Sprague-Dawley, 180-220 g) fasting from the evening before the test, were treated by gastric tube with a single dose of 4% HCA suspension or solution (400 mg/kg; 10 ml/kg) in the following preparations:

- 40 A - Suspension in peanut oil
- B - Suspension in a 85:15 peanut oil: GPGI* mixture
- C - Suspension in soybean oil
- D - Suspension in liquid paraffin
- E - Suspension in fractionated coconut oil
- 45 F - Suspension in a 85:15 fractionated coconut oil: GPGI* mixture
- G - Suspension in GPGI*
- H - Aqueous suspension.

50 At pre-established times (0, 15, 30, 60, 120, 240, 360, 480 minutes) the blood samples (300 µl) were taken from the retro-orbital venous sinus in rats under slight ether anaesthesia. The plasma obtained by centrifugation was then analyzed for its anthocyanosides content by spectrophotometric method (P. Morazzoni et al., Arsneim. Forsch./Drug Res., 41, 128-131, 1991) using as reference a standard scale of anthocyanosides (HCA) in control plasma.

55 C_{max} , area under the curve (AUC) and relative bioavailability (R.B.) of the suspensions A-G versus the aqueous solution H were then calculated according to the following formula:

55

* GPGI = unsaturated polyglycolised glycerides.

AUC (0-480') susp. A-G/Dose HCA

R.B. = -----

5

AUC (0-480') aq. sol. H/Dose HCA

Surprisingly, anthocyanosides plasma levels remarkably higher than those found for the other preparations were obtained only with preparation E (HCA suspension in fractionated coconut oil). Particularly, the relative bioavailability value (R.B.) of suspension E in comparison to the aqueous solution H turned out to be 10 8.77.

The marked bioavailability increase is maintained or even improved by administering 6% (R.B. = 10.8) and 8% (R.B. = 7.8) HCA suspensions, always in fractionated coconut oil.

An increase in the pharmacological activity in the test of capillary fragility follows the bioavailability increase. Male guinea-pigs weighing about 250 g were fed for two weeks with a low content Vitamin C diet 15 (10 mg/kg) so as to obtain animals with reduced capillary resistance. The measure of the capillary resistance was carried out by means of the Charlier vacuometer and it is defined as the depression (in cmHg) which, applied on the animal cutis, causes the appearance of at least 3-4 petechias (R. Charlier et al., Arch. Int. Physiol. Biochim. 71, 1, 1963). The animals were orally treated once a day for three consecutive days with HCA dissolved in water or suspended in fractionated coconut oil.

20 The results reported in Table 2 show that the suspension in fractionated coconut oil is more active than the aqueous solution. The potency ratio calculated 4 hours after the last administration was about 3.5.

From the obtained pharmacokinetic and pharmacological data, the HCA suspension in fractionated coconut oil proves to be remarkably and surprisingly more bioavailable than the aqueous solutions or suspensions in other vegetable or mineral oils.

25 It is known that the bioavailability of water-insoluble, but lipophilic drugs, can be enhanced by formulating them in suitable oily carriers (H. de Nijs, Acta Pharm. Technol., 33(4), 163-168, 1987).

According to the present formulations the HCA, water-soluble and poorly lipophilic, are better absorbed when formulated in an oily suspension in fractionated coconut oil.

The following examples further illustrate the invention.

30

EXAMPLE 1

Gelatine capsules containing 25 mg of V. myrtillus anthocyanosides.

One capsule contains:

35

90% HCA	27.8 mg
Fractionated coconut oil	472 mg

40 27.8 g of HCA are dispersed in 472 g of fractionated coconut oil by means of turbine stirrer, at room temperature, until an homogeneous suspension is obtained, which is deaerated under vacuum and distributed in capsules, dosing at 500 mg/capsule.

EXAMPLE 2

45

Sachets of granulate containing 30 mg of V. myrtillus anthocyanosides.

One sachet contains:

50

55

5	95% HCA	31.6 mg
	Fractionated coconut oil	500 mg
	Mannitol	468.4 mg
	Colloidal silicon dioxide	420 mg
	Pregelatinized starch	210 mg
	Polyvinylpyrrolidone	200 mg
	Talc	59.7 mg
10	Methacrylic acid copolymer (type C)	47 mg
	Triethyl citrate	9.4 mg
	Polyethylene glycol 6000	3.5 mg
	Simethicone emulsion	0.4 mg
	Flavour	45 mg
	Saccharin sodium	5 mg

15 31.6 g of HCA are dispersed in 500 g of fractionated coconut oil with a turbine stirrer at room temperature. 468.4 g of mannitol, 420 g of colloidal silicon dioxide and 210 g of pregelatinized starch are mixed and the HCA suspension in fractionated coconut oil is slowly added kneading in high speed mixer. A 200 g polyvinylpyrrolidone solution in 600 g of alcohol is slowly added to the mixture, which is then
 20 granulated through a 30 mesh sieve and dried under vacuum. The granulate is coated in fluid bed with an aqueous suspension containing polyethylene glycol 6000, triethyl citrate, simethicone emulsion, talc and methacrylic acid copolymer. The coated granulate is added with flavour, saccharin sodium and distributed in sachets, dosing at 2 g/sachet.

25 **EXAMPLE 3**

Tablets containing 15 mg of R. nigrum anthocyanosides.

One tablet contains:

30	80% HCA	18.8 mg
	Fractionated coconut oil	250 mg
	Mannitol	231.1 mg
	Colloidal silicon dioxide	220 mg
35	Pregelatinized starch	105 mg
	Polyvinylpyrrolidone	100 mg
	Talc	29.9 mg
	Methacrylic acid copolymer (type C)	23.5 mg
	Triethyl citrate	4.7 mg
40	Polyethylene glycol 6000	1.8 mg
	Simethicone emulsion	0.2 mg
	Sorbitol	90 mg
	Cross-linked sodium carboxymethylcellulose	20 mg
	Magnesium stearate	5 mg

45 18.8 g of HCA are dispersed in 250 of fractionated coconut oil by means of turbine stirrer at room temperature. 231.1 g of mannitol, 210 g of colloidal silicon dioxide and 105 g of pregelatinized starch are mixed and the HCA suspension in fractionated coconut oil is slowly added kneading in high speed mixer. A 100 g polyvinylpyrrolidone solution in 300 g of alcohol is slowly added to the mixture which is granulated through a 30 mesh sieve and dried under vacuum. The granulate is coated in fluid bed with an aqueous suspension of polyethylene glycol 6000, triethyl citrate, simethicone emulsion, talc and methacrylic acid copolymer. The coated granulate is added with sorbitol, cross-linked sodium carboxymethylcellulose, colloidal silicon dioxide and magnesium stearate and mixed in a cube mixer. The mixture is tabletted dosing at 1.1 g/tablet.

5
10
15
20
25
30
35
40
45
50

Table 1 - Relative bioavailability of HCA (400 mg/kg, 10 mL/kg) in the rat.

Treatment	n° animals	C _{max} µg/mL	AUC (0-480 min) µg min/mL	Relative bioavailability
Suspension in:				
A peanut oil	10	1.31±0.08	222.7±38.8	0.90
B peanut oil: GPGI (85:15)	10	1.89±0.20	349.0±61.8	1.41
C soybean oil	10	1.80±0.17	334.1±24.3	1.35
D liquid paraffin	10	1.70±0.20	222.7±30.9	0.90
E fractionated coconut oil	10	10.73±3.33	2170.2±567.2	8.77
F fractionated coconut oil: GPGI (85:15)	10	6.40±1.28	735.1±139.2	2.47
G GPGI	10	3.98±0.77	594.0±173.3	2.15
Solution in:				
H water	10	1.06±0.14	247.5±38.2	1.00

5
10
15
20
25
30
35
40
45
50

Table 2 - HCA activity in the capillary resistance in guinea-pigs

Treatment	Dose mg/kg/die OS	n. animals	Capillary resistance in cm Hg (m ± e.s.)		
			Day 1 - hours	after treatment	
		0	2	4	6
Controls (coconut oil)	10 mL/kg	6	15.8±0.4	16.2±0.4 10%	15.8±0.4 0%
HCA susp. in fractionated coconut oil	100	6	15.8±0.4	17.0±0.7 31%	17.2±1.0 36%*
	200	6	16.0±0.6	17.8±0.5 49%	18.8±0.5 76%*
Controls (water)	10 mL/kg	6	16.2±0.4	15.8±0.5 -11%	16.0±0.5 -6%*
HCA water solution	200	6	15.8±0.4	16.8±0.7 26%	17.0±0.4 31%*
	400	6	16.0±0.4	17.0±0.4 27%	18.7±0.5 73%*

- (continued) -

Table 2 - HCA activity in the capillary resistance in guinea-pigs - (continued) -

Treatment	Dose mg/kg/die os	n. animals	Capillary resistance in cm Hg (m ± e.s.)
			Day 3 - hours after treatment
		0	2
Controls (coconut oil)	1.0 mL/kg	6	15.8±0.4
HCA susp. in fractionated coconut oil	100	6	16.8±0.5 26%
			0% 17.2±0.5 36%
			0% 16.3±0.4 13%
Controls (water)	10 mL/kg	6	17.3±1.0 35%
HCA water solution	200	6	16.2±0.4 0%
			16.1±0.4 -3%
			16.3±0.4 3%
			15.8±0.4 0%
			15.8±0.4 0%
400	6	17.2±0.5 32%	17.3±0.8 35%
			16.8±0.5 22%
			16.3±0.5 8%

* P < 0.05 Dunnnett's t test versus controls
Percent variation = $(C.R.T - C.R.B) / (C.R.N - C.R.B) \cdot 100$ where:
C.R.T = mean capillary resistance after treatment.
C.R.B = mean basal capillary resistance after low Vitamin C content diet.
C.R.N = mean normal capillary resistance (= 19.7 cm Hg) before the low Vitamin C content diet.

Claims

55 1. Oral pharmaceutical compositions containing as the active principle high content anthocyanosides extracts (HCA) suspended in medium chain fatty acid triglycerides mixtures.

- 2. Pharmaceutical compositions according to claim 1, wherein the anthocyanosides extracts are suspended in fractionated coconut oil.
- 3. Pharmaceutical compositions according to claim 2, characterized in that the anthocyanosides extracts
5 are suspended in fractionated coconut oil in percentages ranging from 2 to 10% w/w.
- 4. Pharmaceutical compositions according to claim 3, characterized in that the anthocyanosides extracts
are suspended in fractionated coconut oil in percentages ranging from 4 to 8% w/w.
- 10 5. Pharmaceutical compositions according to any one of the previous claims characterized in that the high
anthocyanosides extracts contain more than 40% (w/w) anthocyanosides.
- 6. Pharmaceutical compositions according to claim 5, characterized in that the high anthocyanosides
extracts contain more than 50% (w/w) of anthocyanosides.
15
- 7. Pharmaceutical compositions according to claim 6, characterized in that the high anthocyanosides
extracts contain more than 80% (w/w) of anthocyanosides.
- 8. Pharmaceutical compositions according to claims 1-7 in form of capsules, sachets or tablets.
20

25

30

35

40

45

50

55



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number

DOCUMENTS CONSIDERED TO BE RELEVANT			EP 93107265.6									
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. 5)									
A	<u>EP - A - 0 060 553</u> (HUMAN OLTOANYAGTERMELŐ ES KUTATO INTEZET) * Claims; page 3, line 26 - page 4, line 4 * --	1	A 61 K 31/35 A 61 K 35/78 A 61 K 9/10									
D, A	<u>EP - A - 0 412 300</u> (INVERNINI DELLA BEFFA S.P.A.) * Claims * --	1										
A	<u>FR - A - 2 578 165</u> (CHICOURI) * Totality * --	1										
A	<u>FR - A - 2 456 747</u> (SOCIETE CIVILE D' INVESTIGATIONS PHARMACOLOGIQUES D'AQUITAINE) * Claims * --	1										
A	<u>FR - A - 2 268 519</u> (SOCIETE CIVILE D' INVESTIGATONS PHARMACOLOGIQUES D'AQUITAINE) * Claims * ----	1										
			TECHNICAL FIELDS SEARCHED (Int. Cl. 5)									
			A 61 K C 07 H C 07 D 311/00									
<p>The present search report has been drawn up for all claims</p> <table border="1"> <tr> <td>Place of search VIENNA</td> <td>Date of completion of the search 18-08-1993</td> <td>Examiner BECKER</td> </tr> <tr> <td colspan="3"> CATEGORY OF CITED DOCUMENTS <ul style="list-style-type: none"> X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document </td> </tr> <tr> <td colspan="3"> <ul style="list-style-type: none"> T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document </td> </tr> </table>				Place of search VIENNA	Date of completion of the search 18-08-1993	Examiner BECKER	CATEGORY OF CITED DOCUMENTS <ul style="list-style-type: none"> X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document 			<ul style="list-style-type: none"> T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document 		
Place of search VIENNA	Date of completion of the search 18-08-1993	Examiner BECKER										
CATEGORY OF CITED DOCUMENTS <ul style="list-style-type: none"> X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document 												
<ul style="list-style-type: none"> T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document 												